Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 361

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER Trial

Werk, Michael, Albrecht, Thomas, Meyer, Dirk-Roelfs, Ahmed, Mohammed Nabil, Behne, Andrea, Dietz, Ulrich, Eschenbach, Götz, Hartmann, Holger, Lange, Christian, Schnorr, Beatrix, Stiepani, Heiner, Zoccai, Giuseppe Biondi, Hänninen, Enrique Lopez·2012·Circulation: Cardiovascular Interventions

Abstract

Background—: Peripheral percutaneous transluminal angioplasty is fraught with a substantial risk of restenosis and reintervention. A drug-eluting balloon (DEB) based on a novel coating was compared with uncoated balloons in patients undergoing femoro-popliteal percutaneous transluminal angioplasty. Methods and Results—: Patients with symptomatic femoro-popliteal atherosclerotic disease undergoing percutaneous transluminal angioplasty were randomized to paclitaxel-coated IN.PACT Pacific or uncoated Pacific balloons. The primary end point was late lumen loss at 6 months assessed by blinded angiographic corelab quantitative analyses. Secondary end points were binary restenosis and Rutherford class change at 6 months, and target lesion revascularization plus major adverse clinical events (major adverse events=death, target limb amputation, or target lesion revascularization) at 6 and 12 months. Eighty-five patients (91 cases=interventional procedures) were randomized in 3 hospitals (44 to DEB and 47 to uncoated balloons). Average lesion length was 7.0±5.3 and 6.6±5.5cm for DEB and control arm, respectively. Procedural success was obtained in all cases. Six-month quantitative angiography showed that DEB were associated with significantly lower late lumen loss (−0.01mm [95% CI, −0.29; 0.26] versus 0.65mm [0.37; 0.93], P =0.001) and fewer binary restenoses (3 [8.6%] versus 11 [32.4%], P =0.01). This translated into a clinically relevant benefit with significantly fewer major adverse events for DEB versus uncoated balloons up to 12 months (3 [7.1%] versus 15 [34.9%], P <0.01) as well as target lesion revascularizations (3 [7.1%] versus 12 [27.9%], P =0.02). Conclusions—: Use of IN.PACT Pacific DEB is associated with significant reductions in late lumen loss and restenoses at 6 months, and reinterventions after femoro-popliteal percutaneous transluminal angioplasty up to 1 year of follow-up. Clinical Trial Registration—: URL http://www.clinicaltrials.gov . Unique identifier: NCT01083030.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circinterventions.112.971630

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 361

Metadata

Authors
Werk, M., Albrecht, T., Meyer, D.-R., Ahmed, M. N., Behne, A., Dietz, U., Eschenbach, G., Hartmann, H., Lange, C., Schnorr, B., Stiepani, H., Zoccai, G. B., & Hänninen, E. L.
Venue
Circulation: Cardiovascular Interventions
Published
2012-12
Volume
5
Issue
6
Pages
831-840
ISSN
  • 1941-7632 (ISSN-L)
  • 1941-7640
OpenAlex
W2887033821
Cited by
361
References
11
FWCI
27.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.